Genetic testing subsidies for hereditary breast, ovarian cancer to start on Dec 1

The Singapore Ministry of Health (MOH) will begin offering subsidies for genetic testing related to hereditary breast and ovarian cancer (HBOC) starting December 1. About 2,000 people are expected to benefit from the subsidies annually, with costs covering up to 70% of the testing expenses. The test costs approximately S$1,000 before subsidies, but patients with sufficient MediSave balances can use them to cover the remaining costs.

The subsidies will extend to genetic testing for first-degree relatives, such as parents, siblings, and children of those carrying hereditary cancer-linked mutations, a process known as cascade testing. Ms Norain Mohamad Saleh, who was diagnosed with breast cancer at 37, underwent genetic testing that revealed she carries a gene mutation linked to a higher risk of cancer.

This discovery prompted her to encourage her sisters to undergo testing, two of whom tested positive. Knowing her mutation status has left Ms Norain's youngest sister, Norashikin, worried about her own cancer risk, and she is now undergoing regular medical surveillance. Doctors say that identifying gene mutations like BRCA1 and BRCA2 can help family members better understand their cancer risks and take preventive measures, such as earlier screenings or risk-reducing surgery.

Assoc Prof Joanne Ngeow, head of the cancer genetics service at NCCS, welcomed the subsidies, stating that cost was a significant barrier to genetic testing, and the subsidies would ensure equal access to testing and downstream care. However, she emphasized the need for more public education to help families understand the importance of testing and navigate the healthcare system.